Mutagenesis, Vol. 17, No. 4, 265-277,
July 2002
© 2002 UK Environmental Mutagen Society/Oxford University Press
REVIEW |
Aristolochic acid as a probable human cancer hazard in herbal remedies: a review
Section of Molecular Carcinogenesis, Institute of Cancer Research, Cotswold Road, Sutton, Surrey SM2 5NG, UK, 1 Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030, 128 40 Prague 2, The Czech Republic and 2 Division of Molecular Toxicology, German Cancer Research Center, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
The old herbal drug aristolochic acid (AA), derived from Aristolochia spp., has been associated with the development of a novel nephropathy, designated aristolochic acid nephropathy (AAN), and urothelial cancer in AAN patients. There is clear evidence that the major components of the plant extract AA, aristolochic acid I (AAI) and aristolochic acid II (AAII), both nitrophenanthrene carboxylic acids, are genotoxic mutagens forming DNA adducts after metabolic activation through simple reduction of the nitro group. Several mammalian enzymes have been shown to be capable of activating both AAI and AAII in vitro and in cells. The activating metabolism has been elucidated and is consistent with the formation of a cyclic nitrenium ion with delocalized charge leading to the preferential formation of purine adducts bound to the exocyclic amino groups of deoxyadenosine and deoxyguanosine. The predominant DNA adduct in vivo, 7-(deoxyadenosin-N6-yl)aristolactam I (dA–AAI), which is the most persistent of the adducts in target tissue, is a mutagenic lesion leading to AT
TA transversions in vitro. This transversion mutation is found at high frequency in codon 61 of the H-ras oncogene in tumours of rodents induced by AAI, suggesting that dA–AAI might be the critical lesion in the carcinogenic process in rodents. DNA-binding studies confirmed that both AAs bind to the adenines of codon 61 in the H-ras mouse gene and preferentially to purines in the human p53 gene. In contrast, the molecular mechanism of renal interstitial fibrosis in humans after chronic administration of AA remains to be explored. However, preliminary findings suggest that DNA damage by AA is not only responsible for the tumour development but also for the destructive fibrotic process in the kidney. It is concluded that there is significant evidence that AA is a powerful nephrotoxic and carcinogenic substance with an extremely short latency period, not only in animals but also in humans. In particular, the highly similar metabolic pathway of activation and resultant DNA adducts of AA allows the extrapolation of carcinogenesis data from laboratory animals to the human situation. Therefore, all products containing botanicals known to or suspected of containing AA should be banned from the market world wide.
3 To whom correspondence should be addressed. Tel: +44 208 643 8901; Fax: +44 208 770 7290; Email: v.arlt{at}icr.ac.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  V. M. Arlt, M. Stiborova, J. vom Brocke, M. L. Simoes, G. M. Lord, J. L. Nortier, M. Hollstein, D. H. Phillips, and H. H. Schmeiser Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer Carcinogenesis, November 1, 2007; 28(11): 2253 - 2261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Grollman and B. Jelakovic Role of Environmental Toxins in Endemic (Balkan) Nephropathy J. Am. Soc. Nephrol., November 1, 2007; 18(11): 2817 - 2823. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Grollman, S. Shibutani, M. Moriya, F. Miller, L. Wu, U. Moll, N. Suzuki, A. Fernandes, T. Rosenquist, Z. Medverec, et al. Aristolochic acid and the etiology of endemic (Balkan) nephropathy PNAS, July 17, 2007; 104(29): 12129 - 12134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Shibutani, H. Dong, N. Suzuki, S. Ueda, F. Miller, and A. P. Grollman Selective Toxicity of Aristolochic Acids I and II Drug Metab. Dispos., July 1, 2007; 35(7): 1217 - 1222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Chan, H.-B. Luo, Y. Zheng, Y.-K. Cheng, and Z. Cai Investigation of the Metabolism and Reductive Activation of Carcinogenic Aristolochic Acids in Rats Drug Metab. Dispos., June 1, 2007; 35(6): 866 - 874. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Nortier and J.-L. Vanherweghem For patients taking herbal therapy--lessons from aristolochic acid nephropathy Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1512 - 1517. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Stemmer, H. Ellinger-Ziegelbauer, H.-J. Ahr, and D. R. Dietrich Carcinogen-Specific Gene Expression Profiles in Short-term Treated Eker and Wild-type Rats Indicative of Pathways Involved in Renal Tumorigenesis Cancer Res., May 1, 2007; 67(9): 4052 - 4068. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. M. Arlt, E. Frei, and H. H. Schmeiser ECNIS-sponsored workshop on biomarkers of exposure and cancer risk: DNA damage and DNA adduct detection and 6th GUM-32P-postlabelling workshop, German Cancer Research Center, Heidelberg, Germany, 29-30 September 2006 Mutagenesis, January 1, 2007; 22(1): 83 - 88. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. v. Brocke, H. H. Schmeiser, M. Reinbold, and M. Hollstein MEF immortalization to investigate the ins and outs of mutagenesis Carcinogenesis, November 1, 2006; 27(11): 2141 - 2147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Dong, N. Suzuki, M. C. Torres, R. R. Bonala, F. Johnson, A. P. Grollman, and S. Shibutani QUANTITATIVE DETERMINATION OF ARISTOLOCHIC ACID-DERIVED DNA ADDUCTS IN RATS USING 32P-POSTLABELING/POLYACRYLAMIDE GEL ELECTROPHORESIS ANALYSIS Drug Metab. Dispos., July 1, 2006; 34(7): 1122 - 1127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. M. Arlt 3-Nitrobenzanthrone, a potential human cancer hazard in diesel exhaust and urban air pollution: a review of the evidence Mutagenesis, November 1, 2005; 20(6): 399 - 410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Marcus and W. R. Snodgrass Do No Harm: Avoidance of Herbal Medicines During Pregnancy Obstet. Gynecol., May 1, 2005; 105(5): 1119 - 1122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cui, Z.-H. Liu, Q. Qiu, H. Li, and L.-S. Li Tumour induction in rats following exposure to short-term high dose aristolochic acid I Mutagenesis, January 1, 2005; 20(1): 45 - 49. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Liu, M. Hergenhahn, H. H. Schmeiser, G. N. Wogan, A. Hong, and M. Hollstein Human tumor p53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized p53 gene PNAS, March 2, 2004; 101(9): 2963 - 2968. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. S. Gold and T. H. Slone Aristolochic Acid, an Herbal Carcinogen, Sold on the Web after FDA Alert N. Engl. J. Med., October 16, 2003; 349(16): 1576 - 1577. [Full Text] [PDF]
|
|
|
|
|
|
M. Stiborova, E. Frei, B. Sopko, K. Sopkova, V. Markova, M. Lankova, T. Kumstyrova, M. Wiessler, and H. H. Schmeiser Human cytosolic enzymes involved in the metabolic activation of carcinogenic aristolochic acid: evidence for reductive activation by human NAD(P)H:quinone oxidoreductase Carcinogenesis, October 1, 2003; 24(10): 1695 - 1703. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Nortier, H. H. Schmeiser, M.-C. M. Martinez, V. M. Arlt, C. Vervaet, C. H. Garbar, P. Daelemans, and J.-L. Vanherweghem Invasive urothelial carcinoma after exposure to Chinese herbal medicine containing aristolochic acid may occur without severe renal failure Nephrol. Dial. Transplant., February 1, 2003; 18(2): 426 - 428. [Full Text] [PDF]
|
|
|
|
|
|
D. M. Marcus and A. P. Grollman Botanical Medicines -- The Need for New Regulations N. Engl. J. Med., December 19, 2002; 347(25): 2073 - 2076. [Full Text] [PDF]
|
|
|
|
 |
|
 R G Mason and D Donaldson Lessons to be learned: a case study approach: Chinese herbal nephropathy and urothelial malignancy The Journal of the Royal Society for the Promotion of Health, December 1, 2002; 122(4): 266 - 267. [Abstract] [PDF]
|
|